CD79A and COVID-19: This was also observed by Xiao et al. [24], Melayah et al. [25] and Serrano et al. [26] who reported IgA anti-β2GPI as the most frequently occurring aPL in COVID-19 patients (28.8%, 16.9% and 14.9%, respectively).